PDE4

A novel target in the treatment of chronic obstructive pulmonary disease

J. M. Michalski, G. Golden, J. Ikari, Stephen Israel Rennard

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.

Original languageEnglish (US)
Pages (from-to)134-142
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume91
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Chronic Obstructive Pulmonary Disease
Phosphoric Diester Hydrolases
Phosphodiesterase 4 Inhibitors
Wound Healing
Inflammation
Lung
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

PDE4 : A novel target in the treatment of chronic obstructive pulmonary disease. / Michalski, J. M.; Golden, G.; Ikari, J.; Rennard, Stephen Israel.

In: Clinical Pharmacology and Therapeutics, Vol. 91, No. 1, 01.01.2012, p. 134-142.

Research output: Contribution to journalReview article

Michalski, J. M. ; Golden, G. ; Ikari, J. ; Rennard, Stephen Israel. / PDE4 : A novel target in the treatment of chronic obstructive pulmonary disease. In: Clinical Pharmacology and Therapeutics. 2012 ; Vol. 91, No. 1. pp. 134-142.
@article{73e6701fd8094d1e86558215d482af9f,
title = "PDE4: A novel target in the treatment of chronic obstructive pulmonary disease",
abstract = "Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.",
author = "Michalski, {J. M.} and G. Golden and J. Ikari and Rennard, {Stephen Israel}",
year = "2012",
month = "1",
day = "1",
doi = "10.1038/clpt.2011.266",
language = "English (US)",
volume = "91",
pages = "134--142",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - PDE4

T2 - A novel target in the treatment of chronic obstructive pulmonary disease

AU - Michalski, J. M.

AU - Golden, G.

AU - Ikari, J.

AU - Rennard, Stephen Israel

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.

AB - Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.

UR - http://www.scopus.com/inward/record.url?scp=84055207673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055207673&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.266

DO - 10.1038/clpt.2011.266

M3 - Review article

VL - 91

SP - 134

EP - 142

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -